. 2021 Nov 9;16:5–13. doi: 10.1016/j.ejcsup.2021.06.002

Table 8.

Hazard ratios estimated from matching-adjusted indirect comparisons for OS in P-NETs.

	[¹⁷⁷Lu]Lu-DOTA-TATE (reweighted ERASMUS) vs. NCT00428597 (sunitinib) Hazard ratio OS (95% CI)	[¹⁷⁷Lu]Lu-DOTA-TATE (reweighted ERASMUS) vs. NCT00428597 (BSC) Hazard ratio OS (95% CI)	[¹⁷⁷Lu]Lu-DOTA-TATE (reweighted ERASMUS) vs. RADIANT-3 (everolimus) Hazard ratio OS (95% CI)	[¹⁷⁷Lu]Lu-DOTA-TATE (reweighted ERASMUS) vs. RADIANT-3 (BSC) Hazard ratio OS (95% CI)
Main analysis	0.42 [0.25, 0.72]	0.34 [0.20, 0.57]	0.53 [0.33, 0.87]	0.56 [0.36, 0.90]
Sensitivity analysis 1: Incl. non-Dutch ERASMUS patients	0.72 [0.44, 1.16]	0.45 [0.28, 0.72]	0.95 [0.13, 1.48]	0.85 [0.55, 1.32]
Sensitivity analysis 2: Adjusting for all available covariates	NR	NR	NR	NR
Sensitivity analysis 3: Matching to the full comparator population	0.44 [0.27, 0.75]	0.33 [0.20, 0.56]	0.53 [0.33, 0.86]	0.49 [0.30, 0.80]

OS, overall survival; CI, confidence interval; BSC, best supportive care; P-NETs, pancreatic neuroendocrine tumours.

NR: not reported as lack of overlap in populations across all covariates resulted in unreliable results.